Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
SAN RAFAEL, Calif., Jan. 28, 2016 -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 25, at 4:30 p.m. ET to discuss fourth quarter and full year 2015 financial results and provide a general business update.
Dial-in Number
U.S. / Canada Dial-in Number: (877) 303-6313
International Dial-in Number: (631) 813-4734
Conference ID: 34535772
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 34535772
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com.
Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
